<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=348185225613720&amp;ev=PageView&amp;noscript=1">
PacBio Detection_Structural_Variants_Thumbnail

Case Study

Detection of Previously Unidentified Structural Variants Involved in Glioblastoma Using PacBio® Sequel Sequencing 

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Glioblastoma is a devastating disease due in part to its often late-stage diagnosis, rapid progression, and poor survival rates. This case study looks at how GENEWIZ utilized the PacBio Sequel long-read technology to help a customer improve detection of structural variants within glioblastoma samples.

This Case Study discusses:
  • Generation of thousands of long-reads using PacBio Sequel Single Molecule Real Time (SMRT) technology
  • Generation of highly accurate consensus sequences
  • Identification of approximately 20,000 structural variants
  • Future applications

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Download Case Study

 
Share on Social Media:

For technical support questions, please contact our Next Generation Sequencing team

(877) 436-3949 ext. 1 | NGS@genewiz.com